Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.22.2.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating Activities:    
Net loss $ (31,118) $ (26,001)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 4] 171 188
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]] 2,492 1,693
Shares issued as settlement with trade vendor 26 41
Accrued interest on SVB convertible debt [note 7] 863  
Changes in operating assets and liabilities:    
Grant receivable [note 3] 8 (151)
Prepaid expenses and other assets (1,256) (146)
Accounts payable (429) 483
Accrued liabilities other 191 (390)
Accrued clinical liabilities 3,200 304
Accrued compensation (550) (233)
Lease obligation [note 9] (4) (10)
Net cash used in operating activities (26,406) (24,222)
Financing Activities:    
Proceeds from exercise of warrants 24 339
Proceeds from ATM, net of issuance costs [note 8[b]] 1,499  
Financing costs relating to convertible debt with SVB [note 7] (20)  
Proceeds from employee stock purchase plan [note 8[g]] 126  
Taxes paid related to net share settlement of equity awards (47)  
Net cash provided by financing activities 1,582 21,682
Effect of exchange rate changes on cash (1) (1)
Net decrease in cash, cash equivalents and restricted cash (24,825) (2,541)
Cash, cash equivalents and restricted cash at beginning of the period 43,072 35,903
Cash, cash equivalents and restricted cash at end of the period $ 18,247 33,362
May 2021 Public Offering [Member]    
Financing Activities:    
Proceeds from the May 2021 public offering, net of issuance costs   $ 21,343